Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor.

ABSTRACT:

Background

Sarcopenia is a progressive generalized loss of skeletal muscle mass commonly observed in advanced stages of cancer.

Objective

To assess the relationship between sarcopenia and the prognosis of patients with hepatocellular carcinoma (HCC) treated with a programmed cell death 1 (PD-1) inhibitor.

Design

This is a retrospective study.

Methods

This study included patients with HCC treated with camrelizumab between 1 March 2020 and 1 December 2021. The skeletal muscle area at the L3 vertebra middle level was used to calculate the skeletal muscle index. Propensity score matching (PSM) analysis was used to balance the variables between the two groups.

Results

In all, 97 patients with HCC were included in the study, with 46 and 51 patients in the sarc

SUBMITTER: Guo Y 

PROVIDER: S-EPMC9806410 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature